Author

Michele Helbing

Institution: Astellas Pharma (United States)

Observed institution: Astellas Pharma (United States)

ORCID: 0009-0008-1127-8717

Observed ORCID: 0009-0008-1127-8717

OpenAlex ID: A5120100202

Burden of Treatment‐Induced Vasomotor Symptoms in Men With Prostate Cancer on Androgen‐Deprivation Therapy: A Systematic Literature Review

2026 · Mayank Ajmera, Kai-Jye Lou, et al. · Prostate Cancer

MON-206 The Efficacy of Fezolinetant for the Treatment of Vasomotor Symptoms due to Menopause in Individuals with and without Diabetes Mellitus: A Pooled Phase 3 Analysis

2025 · Nanette F Santoro, Martin Blogg, et al. · Journal of the Endocrine Society

Works count: 2

Citation count:

H-index:

I10-index: